Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203287 · ClinicalTrials.gov registry record · Phase 4
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
A Phase 4 study of Neuromuscular Blockade and General Anesthesia, sponsored by The University of Texas Medical Branch, Galveston.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 490
- Enrollment target
- 1
- Study location
NCT07203287: Recruiting Phase 4 study of Neuromuscular Blockade and General Anesthesia, sponsored by The University of Texas Medical Branch, Galveston.
NCT07203287 is a Phase 4 study of Neuromuscular Blockade and General Anesthesia that is actively recruiting participants, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 490 participants, below the 11,759-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07203287, a Phase 4 study of Neuromuscular Blockade and General Anesthesia, is actively recruiting participants, sponsored by The University of Texas Medical Branch, Galveston.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 490 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pulmonary complications than Rocuronium with sugammadex."
Primary Outcome
PPCs will be scored using a grading scale where 0 = no complication, 1 = mild, 2 = moderate, and 3 = severe complication, with 0 as the minimum score and 3 as the maximum score.
Conditions Studied
Interventions
- DRUG Rocuronium
- DRUG Cisatracurium
- DRUG Sugammadex
- DRUG Neostigmine
Study Locations (1)
Texas
- University of Texas Medical Branch - Galveston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2025-08-26 |
| Est. Completion | 2027-08-26 |
| Phase | Phase 4 |
What NCT07203287 shows while recruiting
NCT07203287 is an interventional study that assigns participants to a tested intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap, below the 11,759-participant average among 6 other Neuromuscular Blockade trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Neuromuscular Blockade appearing as the primary indexed condition, and to 4 interventions - of which Rocuronium is the first listed.
NCT07203287 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07203287 about?
NCT07203287 is a clinical study titled "Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease". The purpose of the study is to determine which combination of neuromuscular blocking agent and reversal agent is safer to use during anesthesia for patients with chronic kidney disease. The main question it aims to answer is "The use of Cisatracurium with neostigmine leads to less post-operative pu...
What is the current status of trial NCT07203287?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 490 participants. The study started on 2025-08-26. Estimated completion is 2027-08-26.
What conditions does trial NCT07203287 study?
This clinical trial studies the following conditions: Neuromuscular Blockade, General Anesthesia, Post Operative Pulmonary Complications.
What interventions are being tested in trial NCT07203287?
The interventions under investigation include: Rocuronium (DRUG), Cisatracurium (DRUG), Sugammadex (DRUG), Neostigmine (DRUG).
Who is sponsoring clinical trial NCT07203287?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203287 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromuscular Blockade
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
COMPLETED · Phase 4
-
The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications
COMPLETED · Phase 4
-
Median Versus Ulnar Nerve Quantitative Electromyography Neuromuscular Blockade Monitoring Comparison
RECRUITING
-
NMBA Reversal and Postoperative Urinary Retention
ACTIVE NOT RECRUITING
-
Understanding the Cognition and Decision Making of Community Anesthesiologists
COMPLETED
-
Comparison of Onset of Neuromuscular Blockade With Electromyographic and Acceleromyographic Monitoring
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI